Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure

Results of the ENECA study

I. Édes, Zbigniew Gasior, Krystian Wita

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Aim: To examine the effect of the beta1-selective beta-blocker nebivolol, administered as add-on therapy, on left ventricular function in 260 elderly patients (>65 years) with chronic heart failure (CHF). Methods: The principal inclusion criteria were (1) NYHA class II-IV CHF and (2) a left ventricular ejection fraction (LVEF) ≤35%. The primary end-point was the change in LVEF in response to nebivolol treatment for 8 months. Results: Baseline LVEF values in the two groups were as follows: nebivolol 25.41±7.09% and control 26.41±5.55%. LVEF improved significantly (p=0.027) more in the nebivolol group (6.51±9.15%) than in the control group (3.97±9.20%), the relative improvement (percentage increase in the initial value) being 35.70±57.62% in the nebivolol group and 19.19±40.96% (p=0.008) in the placebo group. Examination of different subgroups did not reveal any heterogeneity in the effects of nebivolol treatment vs. placebo treatment. There were no significant differences between the nebivolol and placebo groups as concerns the changes in clinical status, quality of life, or safety parameters. Conclusion: The findings of the ENECA study confirmed that nebivolol significantly improved cardiac function and proved to be safe and well tolerated in elderly patients with signs of CHF and an impaired LVEF.

Original languageEnglish
Pages (from-to)631-639
Number of pages9
JournalEuropean Journal of Heart Failure
Volume7
Issue number4
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Nebivolol
Left Ventricular Function
Heart Failure
Stroke Volume
Placebos
Therapeutics

Keywords

  • Chronic heart failure
  • Ejection fraction
  • Left ventricular function
  • Nebivolol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure : Results of the ENECA study. / Édes, I.; Gasior, Zbigniew; Wita, Krystian.

In: European Journal of Heart Failure, Vol. 7, No. 4, 06.2005, p. 631-639.

Research output: Contribution to journalArticle

@article{dd4b8255dc534466b372ec1f517c4552,
title = "Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: Results of the ENECA study",
abstract = "Aim: To examine the effect of the beta1-selective beta-blocker nebivolol, administered as add-on therapy, on left ventricular function in 260 elderly patients (>65 years) with chronic heart failure (CHF). Methods: The principal inclusion criteria were (1) NYHA class II-IV CHF and (2) a left ventricular ejection fraction (LVEF) ≤35{\%}. The primary end-point was the change in LVEF in response to nebivolol treatment for 8 months. Results: Baseline LVEF values in the two groups were as follows: nebivolol 25.41±7.09{\%} and control 26.41±5.55{\%}. LVEF improved significantly (p=0.027) more in the nebivolol group (6.51±9.15{\%}) than in the control group (3.97±9.20{\%}), the relative improvement (percentage increase in the initial value) being 35.70±57.62{\%} in the nebivolol group and 19.19±40.96{\%} (p=0.008) in the placebo group. Examination of different subgroups did not reveal any heterogeneity in the effects of nebivolol treatment vs. placebo treatment. There were no significant differences between the nebivolol and placebo groups as concerns the changes in clinical status, quality of life, or safety parameters. Conclusion: The findings of the ENECA study confirmed that nebivolol significantly improved cardiac function and proved to be safe and well tolerated in elderly patients with signs of CHF and an impaired LVEF.",
keywords = "Chronic heart failure, Ejection fraction, Left ventricular function, Nebivolol",
author = "I. {\'E}des and Zbigniew Gasior and Krystian Wita",
year = "2005",
month = "6",
doi = "10.1016/j.ejheart.2004.10.015",
language = "English",
volume = "7",
pages = "631--639",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure

T2 - Results of the ENECA study

AU - Édes, I.

AU - Gasior, Zbigniew

AU - Wita, Krystian

PY - 2005/6

Y1 - 2005/6

N2 - Aim: To examine the effect of the beta1-selective beta-blocker nebivolol, administered as add-on therapy, on left ventricular function in 260 elderly patients (>65 years) with chronic heart failure (CHF). Methods: The principal inclusion criteria were (1) NYHA class II-IV CHF and (2) a left ventricular ejection fraction (LVEF) ≤35%. The primary end-point was the change in LVEF in response to nebivolol treatment for 8 months. Results: Baseline LVEF values in the two groups were as follows: nebivolol 25.41±7.09% and control 26.41±5.55%. LVEF improved significantly (p=0.027) more in the nebivolol group (6.51±9.15%) than in the control group (3.97±9.20%), the relative improvement (percentage increase in the initial value) being 35.70±57.62% in the nebivolol group and 19.19±40.96% (p=0.008) in the placebo group. Examination of different subgroups did not reveal any heterogeneity in the effects of nebivolol treatment vs. placebo treatment. There were no significant differences between the nebivolol and placebo groups as concerns the changes in clinical status, quality of life, or safety parameters. Conclusion: The findings of the ENECA study confirmed that nebivolol significantly improved cardiac function and proved to be safe and well tolerated in elderly patients with signs of CHF and an impaired LVEF.

AB - Aim: To examine the effect of the beta1-selective beta-blocker nebivolol, administered as add-on therapy, on left ventricular function in 260 elderly patients (>65 years) with chronic heart failure (CHF). Methods: The principal inclusion criteria were (1) NYHA class II-IV CHF and (2) a left ventricular ejection fraction (LVEF) ≤35%. The primary end-point was the change in LVEF in response to nebivolol treatment for 8 months. Results: Baseline LVEF values in the two groups were as follows: nebivolol 25.41±7.09% and control 26.41±5.55%. LVEF improved significantly (p=0.027) more in the nebivolol group (6.51±9.15%) than in the control group (3.97±9.20%), the relative improvement (percentage increase in the initial value) being 35.70±57.62% in the nebivolol group and 19.19±40.96% (p=0.008) in the placebo group. Examination of different subgroups did not reveal any heterogeneity in the effects of nebivolol treatment vs. placebo treatment. There were no significant differences between the nebivolol and placebo groups as concerns the changes in clinical status, quality of life, or safety parameters. Conclusion: The findings of the ENECA study confirmed that nebivolol significantly improved cardiac function and proved to be safe and well tolerated in elderly patients with signs of CHF and an impaired LVEF.

KW - Chronic heart failure

KW - Ejection fraction

KW - Left ventricular function

KW - Nebivolol

UR - http://www.scopus.com/inward/record.url?scp=19544370840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19544370840&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2004.10.015

DO - 10.1016/j.ejheart.2004.10.015

M3 - Article

VL - 7

SP - 631

EP - 639

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 4

ER -